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Abstract 
 
  Previous studies have examined the therapeutic effect of endothelial progenitor cells 
(EPCs) during the chronic phase of cerebral infarction in rats; however, few studies have 
investigated the effects of EPCs during the acute phase of infarction. In this study, we 
evaluated the therapeutic effect of EPCs with low aldehyde dehydrogenase activity 
(Alde-Low EPCs) in rats with acute cerebral infarction, and our results provide insight that 
may help to identify a therapeutic mechanism of EPCs for acute cerebral infarction. The 
administration of Alde-Low EPCs into rats with acute cerebral infarction results in the 
accumulation and migration of the Alde-Low EPCs into the infarct area and the subsequent 
decrease of infarct volume. Moreover, we found that the stromal cell-derived factor-1 
(SDF-1) and CXC chemokine receptor 4 (CXCR4) signaling pathway may regulate the 
accumulation of Alde-Low EPCs. The transplantation of Alde-Low EPCs may represent a 
potential treatment strategy for acute cerebral infarction. 
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1. Introduction 
 
  Due to recent developments in regenerative medicine and cell technology, cell therapy 
has shown great promise as a new treatment for ischemic stroke. In fact, a variety of cell 
types are currently being investigated as potential therapeutic agents: neural 
stem/progenitor cells, mesenchymal stem cells, endothelial progenitor cells (EPCs), 
embryonic stem (ES) cells, and induced pluripotent stem (iPS) cells [1,2,3,4]. 
 Asahara and colleagues first identified EPCs as a subpopulation of the leukocyte fraction 
of human peripheral blood [5]. Recent studies have suggested that EPCs contribute to 
tissue vascularization during both physiological and pathological processes, e.g., wound 
healing and cancer, respectively [6,7]. In particular, there has been a growing interest in 
EPCs as potential therapeutic agents for ischemic disorders because of their ability to 
promote recovery after ischemic events, such as hind limb ischemia and myocardial 
infarction [6]. In stroke, however, EPC studies have been limited [8].  
  We have recently identified a population of EPCs derived from umbilical cord blood 
(UCB) that is suitable for the treatment of ischemic tissue [9]. We divided EPCs into two 
subpopulations based on the level of their aldehyde dehydrogenase (ALDH) activity and 
consequently found that EPCs with low ALDH activity (Alde-Low EPCs) possessed a 
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greater ability to proliferate and migrate compared with EPCs with high ALDH activity 
(Alde-High EPCs). In addition, previous studies have shown that the introduction of 
Alde-Low EPCs significantly reduced tissue damage in the ischemic condition of a mouse 
skin flap model [9]. 
  Here, we confirmed the therapeutic effect of Alde-Low EPCs for acute cerebral 
infarction using a rat ischemia/reperfusion model. 
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2. Materials and Methods 
 
2.1. Preparation of cells for administration 
 
  Alde-Low EPCs, Alde-High EPCs, and human umbilical vein endothelial cells 
(HUVECs) were prepared as previously described [9] and as briefly summarized below.  
Human full-term UCB samples were collected from umbilical cord veins with 
permission from the local ethics committee of the University of Tsukuba. Mononuclear 
cells were separated from the UCB by density gradient centrifugation and cultured in 
medium consisting of Iscove's Modified Dulbecco's Medium (IMDM; Invitrogen, Carlsbad, 
CA) with fetal bovine serum (FBS; Hyclone, South Logan, UT), L-glutamine (Invitrogen), 
and human basic fibroblast growth factor (hb-FGF; Peprotech, London, UK) in a flask 
without a specific surface coating. The adherent cells were analyzed for their incorporation 
of the PE-conjugated, low-density lipoprotein from the human plasma acetylated Dil 
complex (DiI-Ac-LDL; Molecular Probes, Eugene, OR); this marker is observed in both 
endothelial cells and macrophages. After the Dil-Ac-LDL assay, the cells were sorted into 
CD45-/CD31+/Dil-Ac-LDL+ subpopulations by fluorescence-activated cell sorting (FACS) 
to exclude macrophages and monocytes. The sorted cells were then expanded for further 
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experiments. When grown on a Matrigel substrate, these cells formed capillary tube-like 
structures that resembled the morphology of endothelial cells. Because these cells 
exhibited responses and properties that were similar to those of EPCs, we concluded that 
they were EPCs. The UCB-derived EPCs were further separated according to ALDH 
activity into Alde-High and Alde-Low cells. The ALDH activity was analyzed using an 
Aldefluor reagent (StemCell Technologies, Vancouver, BC) [10], and the cells were sorted 
by FACS. The HUVECs were purchased from Cambrex (Walkersville, MD) and 
maintained in endothelial cell basal medium 2 (EBM-2; Cambrex). 
  The cultured HUVECs, Alde-High EPCs, and Alde-Low EPCs were transfected with 
green fluorescent protein (GFP) as described previously [11], and the GFP-labeled 
HUVECs and EPCs were purified using FACSVantage (BD Biosciences, San Jose, CA). 
 
2.2. Transient middle cerebral artery occlusion (MCAo) and transarterial cell 
transplantation 
 
  All of the animal experiments were performed in a humane manner following approval 
from the Animal Experiment Committee of the University of Tsukuba and in accordance 
with the Regulation for Animal Experiments Committee of the University of Tsukuba.  
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  Transient middle cerebral artery occlusion (MCAo) model was selected for the similarity 
with clinical condition during acute phase of ischemia, because reperfusion occured in 
20% of patients within 24 hours after MCAo and 80% of patient within seven days [12,13]. 
  Male Sprague-Dawley rats weighing 280-320 g were purchased from Charles River 
Japan Inc. (Yokohama, Japan). The induction of MCAo is an established technique in our 
laboratory and has been previously described [14]. In brief, after ligation of both the right 
common carotid artery (CCA) and the external carotid artery, a 4-0 nylon suture (Alfresa 
Pharma, Osaka, Japan) with silicon coating (Dow Corning Corporation, Midland, MI) on 
the tip was introduced from the CCA via the internal carotid artery (ICA) into the anterior 
cerebral artery (ACA) until the origin of middle cerebral artery (MCA) was occluded. 
Reperfusion was achieved by withdrawal of the suture following a transient occlusion of 
the MCA for 60 minutes. A neurological deficit, consisting of a left-sided hemiparesis and 
Horner’s syndrome on the right side, was evaluated at 30 minutes and 24 hours after 
reperfusion using the modified Neurological Examination Grading System [15], and the 
regional cerebral cortical blood flow (rCoBF) was simultaneously measured trans-cranially 
using a Laser Doppler flowmeter (ADVANCE, Kyoto, Japan). The neurological deficit and 
the rCoBF were used as the criteria for a successful ischemic insult.  
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  Thirty minutes after reperfusion of the MCA, the rats received an injection of HUVECs, 
Alde-High EPCs, or Alde-Low EPCs (5×105 cells) with 0.5 ml of phosphate-buffered 
saline (PBS) into the CCA via the same route through which the occluded suture was 
withdrawn. Immunosuppression was induced using an intraperitoneal injection of 
cyclophosphamide (cyclosporine-A; Wako, Osaka, Japan) at 10 mg/kg body weight 24 
hours before and immediately after the transplantation. 
 
2.3. Measurement of infarct volume 
 
  Twenty-four hours after transplantation, the rats were anesthetized with a lethal dose of 
intraperitoneal pentobarbital and perfused with PBS via the ascending aorta. The brains 
were carefully removed and cut into seven serial coronal slices (each 2 mm in thickness) 
from the frontal pole. These sections were stained with 2,3,5-triphenyltetrazolium chloride 
(TTC) at 37°C for 30 minutes and imaged to calculate the volume of the infarct areas using 
SCION Image (SCION Corporation, Frederick, MD). We calculated the ratio of the total 
infarct area of the seven coronal sections to the contralateral hemisphere (% infarct 
volume) as the total infarct volume to reduce the distortion of the infarct area by brain 
edema. 
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2.4. Immunohistochemical and quantitative analysis of GFP-positive cells in the cerebral 
hemisphere 
 
  Twenty-four hours after cell transplantation, the perfused brains were removed as 
previously described. The brains were cut into 2-mm-thick coronal slices at the level of the 
caudate-putamen (6-8 mm caudal from the frontal pole); these slices included the MCA 
perfusion area. The sections were perfused with 4% phosphate-buffered paraformaldehyde 
(PBPA) for 24 hours and cryoprotected with 20% sucrose in PBS for an additional 24 
hours. The fixed brain slices were then sliced into 10-µm-thick coronal sections. The 
sections were incubated with the following primary antibodies: a monoclonal mouse 
antibody against α-smooth muscle actin (α-SMA; DAKO, Glostrup, Denmark) and a rabbit 
polyclonal antibody against SDF-1 (Santa Cruz Biotechnology, Inc. Santa Crus, CA). 
Following incubation, the sections were then incubated with the following secondary 
antibodies: Alexa Fluor 555 goat anti-mouse (Invitrogen) and Alexa Fluor 555 goat 
anti-rabbit. The sections were counterstained with 4’,6-diamidino-2-phenylindole 
dihydrochloride (DAPI; Roche Diagnostics-Applied Science, Mannheim, Germany). The 
entire hemispheric area was observed by fluorescence microscopy (Biozero, BZ8000, 
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KEYENCE Inc., Osaka, Japan) for the detection and quantitative analysis of GFP-positive 
cells within designated rectangular regions (400 µm × 300 µm) for each rat in a consistent 
manner.  
 
2.5. Analysis of the involvement of the SDF-1/CXCR4 signaling pathway in the 
accumulation of Alde-Low EPCs 
 
  To assess the involvement of the SDF-1/CXCR4 pathway in the accumulation of 
Alde-Low EPCs, we transplanted Alde-Low EPCs with CXCR4 down-regulation using 
small interfering RNAs (siRNAs) in MCAo rats. Stable down-regulation of CXCR4 was 
achieved by transduction of a lentiviral vector with the expression of short hairpin RNA for 
CXCR4 (CXCR4 shRNA), generated in the MISSION TRC-Hs1.0 (Sigma-Aldrich, 
Steinheim, Germany; the clone number is TRCN0000004053, and the sequence inserted to 
the vector was 
5’-CCGGCATCATCTTCTTAACTGGCATCTCGAGATGCCAGTTAAGAAGATGATGT
TTTT-3’). After incubating the Alde-Low EPCs for 24 hours in a 24-well plate (until the 
cells reached 80% confluency), 200 µl media and hexadimethrine bromide 
(Sigma-Aldrich; final concentration 8 µg/ml) were added to each well to enhance the 
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transduction efficiency. After the addition of 20 µl of the CXCR4 shRNA (Sigma-Aldrich) 
to the appropriate wells and an additional 48 hours of incubation, the Alde-Low EPCs that 
had been transduced with CXCR4 shRNA were selected using puromycin (Sigma-Aldrich; 
final concentration 2 µg/ml). Reverse-transcription–polymerase chain reaction (RT-PCR) 
revealed that CXCR4 gene expression had decreased to 14%. The CXCR4 primers used 
were 5’-CTGTGACCGCTTCTACCCCAATGACTT-3’ and 
5’-CTTGGGGTAGGAGATACGAAAGGAACC-3’. 
The Alde-Low EPCs that had been down-regulated by the CXCR4 shRNA (Alde-Low 
EPCs CXCR4si) were also transfected with GFP. We evaluated the infarct volume and the 
accumulation of Alde-Low EPCs CXCR4si 24 hours after cell transplantation, as described 
above.  
 
2.6. Statistical analysis 
 
  The values obtained in this study were statistically evaluated using Student’s t-test for 
per-comparison analyses. All of the values are presented as the means ± SD.  
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3. Results 
 
3.1. Reduction of the infarct volume 
 
Twenty-four hours after the transplantation of EPCs, we examined the infarct lesions, 
which could be identified as unstained areas by TTC-staining (Fig. 1A-D). Interestingly, 
the infarct volume was significantly reduced in the rats of the Alde-Low EPC transplanted 
group (Fig. 1D) compared with the PBS, HUVECs, or Alde-High EPC transplanted group 
(Fig. 1A-C). The infarct volumes (% infarct volume) in each group were as follows: PBS, 
77.0% ± 16.9%; HUVECs, 72.4% ± 18.2%; Alde-High EPCs, 63.1% ± 22.0%; and 
Alde-Low EPCs, 37.1% ± 10.4% (PBS or HUVECs vs. Alde-Low, p < 0.0005; Alde-High 
vs. Alde-Low, p < 0.005, n = 10) (Fig. 1E). 
 
3.2. Distribution and accumulation of GFP-positive cells 
 
In the Alde-Low EPC transplantation group, a larger number of GFP-positive cells had 
accumulated on the ischemic side compared with the control side (Fig. 2A, 2B), despite the 
lack of laterality in the distribution of GFP-positive cells in the HUVECs and Alde-High 
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EPC transplanted groups. The GFP-positive cells were detected morphologically as 
spindle-shaped cells with cytoplasmic GFP fluorescence and nuclear DAPI fluorescence or 
a round nuclear defect (Fig. 2C-E). In the Alde-Low EPC transplanted group, we observed 
scattered groups of GFP-positive cells that were localized within the cerebral parenchyma 
of the striatum and lateral cortex of the infarct side (Fig. 2F), indicating migration of the 
Alde-Low EPCs. Quantitative analysis of GFP-positive cells per hemisphere revealed that 
significantly greater numbers of GFP-positive cells were detected on the infarct side of the 
Alde-Low EPCs transplanted group (Fig.3). Consequently, the Alde-Low EPCs specifically 
accumulated on the infarct side even under the acute experimental conditions. The number 
of GFP-positive cells per hemisphere was as follows: HUVECs on the infarct side, 88.7 ± 
9.5 cells per hemisphere; Alde-High on the infarct side, 118.3 ± 18.8; Alde-Low on the 
control side, 132.3 ± 48.0; Alde-Low on the infarct side, 318.7 ± 89.8 (HUVECs or 
Alde-High vs. Alde-Low on the infarct side, p < 0.05; Alde-Low on the control side vs. the 
infarct side, p < 0.05, n = 3) (Fig. 3).  
 
3.3. Involvement of the SDF-1/CXCR4 pathway in the accumulation of Alde-Low EPCs 
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  Fluorescent analysis revealed the expression of SDF-1 in the endothelial cells of 
capillaries in all the groups, and we found that the GFP-positive cells had accumulated in 
the capillaries (Fig. 4A). In addition, in the Alde-Low EPC CXCR4si transplanted group, 
the number of GFP-positive cells on the infarct side was reduced and the infarct volume 
had increased compared with the Alde-Low EPC transplanted group (Fig. 4B). 
Consequently, down-regulation of CXCR4 in the Alde-Low EPCs decreased their 
accumulation in the ischemic area. The number of GFP-positive cells in the Alde-Low 
EPCs CXCR4si transplanted group was 127.0 ± 6.1 cells per hemisphere, compared with 
318.7 ± 89.0 cells per hemisphere observed in the Alde-Low EPC group (p < 0.05, n = 3). 
Moreover, the infarct volumes were 53.0% ± 11.8% in the Alde-Low EPC CXCR4si 
transplanted group and 37.1 ± 10.4% in the Alde-Low EPCs group (p < 0.05, n = 3) (Fig. 
4B). 
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4. Discussion 
 
  EPC transplantation therapy shows great promise as a therapeutic option for ischemic 
disorders because of the ability of EPCs to promote recovery after ischemic events [6,16]. 
However, there have been limited EPC studies investigating the acute phase of stroke 
[8,17]. Moreover, the identification and isolation of EPCs have been controversial issues 
within the research community [18]. EPCs were originally characterized by their cell 
surface expression of CD34, CD133 and VEGFR-2 [5]; therefore, EPCs have been 
predominantly defined based on the expression of cell surface markers. EPCs can be 
isolated from a variety of sources, such as peripheral blood [19], bone marrow [17], spleen 
[20], adipose tissue [21,22], ES cells [2,23], and the UCB [9,24]. Because of their diverse 
origins, it has been unclear which type of EPC is the most suitable for cell therapy for 
stroke and other ischemic disorders. 
  Some studies examined the therapeutic time window of EPC transplantation during the 
chronic phase in a model of cerebral ischemia [1]. Another study of autologous 
mononuclear cell transplantation for cerebral ischemia in rats at 3-72 hours after induction 
of MCAo reported that the earlier administration of cells was more effective at decreasing 
the lesion size and increasing the functional outcome [25]. However, few studies have 
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reported on the beneficial effect of EPC transplantation during the acute phase, which is 
considered to be within 24 hours of transplantation [17,26]. 
  In this study, we confirmed that transplantation of Alde-Low EPCs specifically 
attenuated the infarct volume and that EPCs accumulated in the ischemic region 24 hours 
after induction of MCAo in rats. These results are consistent with our previous study of 
Alde-Low EPC transplantation using the mouse skin flap model. However, during the 
acute phase of ischemia, the therapeutic mechanisms of EPCs remain unclear. During acute 
phase, trophic factors may also contribute to the therapeutic effects for cerebral ischemia 
through several different mechanisms, including free radical scavenging, anti-apoptotic 
activity, and anti-inflammatory activity, thereby reducing secondary brain damage after 
cerebral infarction [17,25,27,28].  
  We found the specific accumulation of Alde-Low EPCs at the ischemic site during the 
acute phase to be particularly interesting. To investigate the therapeutic mechanism of 
Alde-Low EPCs, we investigated the ability of the SDF-1/CXCR4 signaling pathway to 
mediate the accumulation of Alde-Low EPCs. CXCR4, a 7-transmembrane spanning 
G-protein-coupled receptor, is expressed on different types of stem cells, progenitor cells, 
and mature endothelial cells. The chemokine SDF-1 is a proinflammatory cytokine 
involved in cell trafficking and adhesion and binds exclusively to its cognate receptor, 
                                         17 
CXCR4 [29,30,31]. Many studies have shown that the SDF-1/CXCR4 signaling pathway 
regulates angiogenesis and vasculogenesis during development via the mobilization, 
migration and differentiation of EPCs [30,32,33]. In addition, SDF-1 is expressed in the 
ischemic area even during the acute phase [34]. We have previously demonstrated that 
CXCR4 expression increased significantly in the Alde-Low EPCs compared with the 
Alde-High or control cells under hypoxic conditions and that Alde-Low EPCs have a 
higher migratory activity in vitro compared with Alde-High EPCs [9]. Moreover, we used 
CXCR4 siRNA to specifically block SDF-1/CXCR4 signaling [35,36]. We confirmed that 
Alde-Low EPCs CXCR4si exhibited a reduced ability to accumulate in vivo, strongly 
suggesting that SDF-1/CXCR4 signaling plays an important role in the accumulation of 
Alde-Low EPCs during the acute phase of ischemia. 
  In future studies, we intend to investigate the functional properties of Alde-Low EPCs 
and investigate the therapeutic mechanism in the sub-acute and chronic phases of 
infarction in addition to the acute phase. 
 We demonstrated that a specific subpopulation of EPCs, characterized by low ALDH 
activity, exerted a therapeutic effect and specifically accumulated in the ischemic area 
during the acute phase of stroke. We therefore concluded that transplantation of Alde-Low 
EPCs might be a promising strategy for the treatment of acute cerebral infarction. However, 
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further studies are essential to determine the safety, effectiveness and efficiency of EPC 
therapy for clinical application. 
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Figure Legends 
 
Fig. 1. Alde-Low EPCs reduced infarct volume at 24 hours after transplantation. (A-D) 
Representative coronal brain sections stained with 2,3,5-triphenyltetrazolium chloride from 
the PBS injection group (A), HUVECs group (B), Alde-High EPC transplanted group (C), 
and Alde-Low EPC transplanted group (D). The infarct area (white) was significantly 
reduced in the Alde-Low EPC transplanted group (D). (E) The infarct volumes (% infarct 
volume) in the 4 groups of rats (n = 10) were measured. It should be noted that the smallest 
infarct volume was observed in the Alde-Low EPCs transplanted group (*p < 0.005, **p < 
0.0005).  
 
Fig. 2. The distribution and accumulation of GFP-positive cells in the Alde-Low 
transplanted group 24 hours after transplantation. Fluorescent immunohistochemical 
analyses were performed (A-F). (A) and (D) show the control side and (B), (C), (E) and (F) 
show the ischemic side. A larger number of GFP-positive cells (green) accumulated to the 
ischemic side (B) compared with the control side (A) in the caudate-putamen. (C) The 
GFP-positive cells were identified morphologically as spindle-shaped cells with 
cytoplasmic GFP fluorescence and nuclear DAPI fluorescence or as a round nuclear defect 
(arrow) localized predominantly on the capillaries stained with α-SMA (red; arrowheads). 
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We quantified the GFP-positive cells, which were mainly found on the capillaries (D, E). 
Specifically in the Alde-Low EPC transplanted group, the migration of GFP-positive cells 
was observed to be localized within the cerebral parenchyma of the striatum and lateral 
cortex on the infarct side (F) as well as on the capillaries (E). Scale bars = 50 µm (A, B), 
100 µm (C-F). 
 
Fig. 3. The quantitative analysis of GFP-positive cells in each group that distributed to the 
control or ischemic hemisphere. It should be noted that the Alde-Low EPCs specifically 
accumulated on the ischemic side compared with the ischemic side of the control, the 
HUVEC and Alde-High EPC transplanted groups (*p < 0.05).  
 
Fig. 4. Involvement of the SDF-1/CXCR4 signaling pathway. We observed the expression 
of SDF-1 in the endothelial cells of capillaries within the ischemic area 24 hours after 
MCAo (A). The GFP-positive cells (green) had accumulated toward the SDF-1-expressing 
endothelial cells (red) (A). In the Alde-Low EPC CXCR4si transplanted group, the number 
of GFP-positive cells on the infarct side was reduced and the infarct volume had increased 
compared with the Alde-Low EPC transplanted group (B). Consequently, down-regulation 
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of CXCR4 in the Alde-Low EPCs decreased their accumulation within the ischemic area 
(*p < 0.05, **p < 0.005). Scale bars = 100 µm. 
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